PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Webcasts|September 1, 2020
Improve Pharmaceutical Methods with Automatic Titration
Author(s)Metrohm
In this webcast, Brett Lane, Senior Chemist of Lonza’s QC laboratory in Rochester, NY will share his experience modifying titration manual methods to optimize results using autotitration. Live: Wednesday, Sept. 23, 2020 at 1pm EDT | 12pm CDT | 10am PDT On demand available after final airing until Sept. 23, 2021
Register free:
Event Overview:
Using manual titration to perform quality control of pharmaceutical raw materials, APIs, intermediates and final products invites error into very important steps of the pharmaceutical manufacturing process. With the right method development support, getting a manual titration migrated to an autotitrator is a simple process.
In this webcast, Brett Lane, Senior Chemist of Lonza’s QC laboratory in Rochester, NY will share his experience modifying manual titration methods to optimize results using autotitration. Brett will use two case studies, sodium and zinc pyrithione fungicides and bactericides, to walk through the method development and validation process. Kerri-Ann Blake, Product Manager for Titration at Metrohm, will provide tips for converting manual titrations to modern automatic titrations. She will also share how it’s possible to automate colorimetric titrations and satisfy USP requirements and how to select the best system for the analysis.
Key Learning Objectives:
- Learn how to develop and validate titration methods for pharmaceutical products
- Understand how to adjust parameters to optimize titration methods
- Learn how convert manual titrations to automatic titrations
- Learn best practices for maintaining titration instrumentation
Speakers:
Brett Lane, Senior Chemist, Lonza
Dr. Kerri-Ann Blake, Titration Product Manager, Metrohm USA
Time and Date: Wednesday, Sept. 23, 2020 at 1pm EDT | 12pm CDT | 10am PDT
On demand available after final airing until Sept. 23, 2021
Sponsor: Metrohm
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.